Adaptimmune secures $225m of new funding
Adaptimmune Therapeutics, the New York-listed UK biopharmaceutical company focused on cancer treatments, has raised $225m to fund further clinical trials for its immunotherapy treatments.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: